Molecular Partners AG (MOLN) IPO Opens Modestly Lower

Today's IPO for Molecular Partners AG (NASDAQ: MOLN) opened for trading at $20 after pricing 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS.

J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

You May Also Be Interested In

• Scribe Therapeutics raises $155.51M in IPO on Nasdaq
• Market Technology Acquisition Corp prices $200M IPO on Nasdaq
• Apnimed (APMD) files for 10M share IPO at $14-$16/sh